Last updated: 07/17/2024 17:34:14
Efficacy and safety study of GSK3772847 in subjects with moderately severe asthma
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A randomized, double-blind, parallel group, multicenter, stratified study evaluating the efficacy and safety of repeat doses of GSK3772847 compared with placebo in participants with moderately severe asthma
Trial description: GSK3772847, an anti-interleukin (IL)33 receptor monoclonal antibody, is a novel treatment for asthma. This is a phase 2a study which aims to evaluate efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of GSK3772847 in subjects with moderately severe asthma. The study will be conducted in 4 phases including screening, run-in phase, treatment phase and follow-up. In treatment phase, eligible subjects will be randomized to receive either GSK3772847 or placebo administered via intravenous (IV) route every 4 weeks in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. During the treatment phase, the background therapy will be switched to FP 500 mcg for 2 weeks and the dose of FP will be reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. The total duration of study will be approximately 33 weeks and approximately 165 subjects with moderately severe asthma who are maintained on high-dose of inhaled corticosteroids/ Long-Acting Beta-2-Agonists (ICS/LABA) will be randomized.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Number of subjects with loss of asthma control
Timeframe: Up to Week 16
Secondary outcomes:
Number of subjects with a more than or equal to 0.5 point increase from Baseline in ACQ-5 score
Timeframe: Up to Week 16
Number of subjects who have a Pre-bronchodilator FEV1 decrease from Baseline more than 7.5 percent
Timeframe: Up to Week 16
Number of subjects where ICS can not be titrated in accordance with the pre-defined schedule
Timeframe: Up to Week 16
Number of subjects who have a significant asthma exacerbation
Timeframe: Up to Week 16
Time to loss of asthma control
Timeframe: Up to Week 16
Number of subjects with a clinically significant asthma exacerbation or inability to titrate ICS according to the pre-defined schedule
Timeframe: Up to Week 16
Number of hospitalization or emergency room (ER) visits per subject
Timeframe: Up to Week 16
Mean rate of hospitalization or ER visits
Timeframe: Up to Week 16
Change from Baseline in ACQ-5 absolute score at each week
Timeframe: Baseline and up to Week 16
Number of subjects with more than or equal to 0.5 point decrease from Baseline in ACQ-5 score at each week
Timeframe: Up to Week 16
Change from Baseline in St. George’s Respiratory Questionnaire (SGRQ) total score at Week 4, 8, 12 and 16
Timeframe: Baseline and up to Week 16
Number of SGRQ responders at Week 4, 8, 12 and 16
Timeframe: Up to Week 16
Change from Baseline in pre-bronchodilator FEV1
Timeframe: Baseline and up to Week 16
Change from Baseline in mean morning expiratory flow (PEF) and mean evening PEF
Timeframe: Baseline and up to Week 16
Change from Baseline in mean daytime asthma symptom score
Timeframe: Baseline and up to Week 16
Change from Baseline in rescue medication use
Timeframe: Baseline and up to Week 16
Changes from Baseline in night-time awakenings due to asthma symptoms requiring rescue medication use
Timeframe: Baseline and up to Week 16
Change from Baseline in fractional exhaled nitric oxide (FeNO)
Timeframe: Baseline and up to Week 16
Number of adverse events (AEs) and serious adverse events (SAEs)
Timeframe: Up to Week 16
Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Timeframe: Baseline and up to Week 28
Change from Baseline in pulse rate
Timeframe: Baseline and up to Week 28
Change between post-dose and pre-dose in SBP and DBP at Week 0, 4, 8 and 12
Timeframe: Up to Week 12
Change between post-dose and pre-dose in pulse rate at Week 0, 4, 8 and 12
Timeframe: Up to Week 12
Change from Baseline in 12-lead Electrocardiogram (ECG) findings at Week 4, 8, 12 and 16
Timeframe: Baseline and up to Week 16
Change between post-dose and pre-dose in 12-lead ECG readings at Week 0, 4, 8 and 12
Timeframe: Up to Week 12
Change from Baseline in Holter measurements at Week 4 and 12
Timeframe: Baseline and up to Week 12
Change from Baseline in platelet, Red Blood Cell (RBC) and White Blood Cell (WBC) count
Timeframe: Baseline and up to Week 28
Change from Baseline in Hemoglobin level
Timeframe: Baseline and up to Week 28
Change from Baseline in hematocrit level
Timeframe: Baseline and up to Week 28
Change from Baseline in Mean Corpuscular Hemoglobin (MCH)
Timeframe: Baseline and up to Week 28
Change from Baseline in Mean Corpuscular Volume (MCV)
Timeframe: Baseline and up to Week 28
Change from Baseline in Mean corpuscular hemoglobin concentration (MCHC)
Timeframe: Baseline and up to Week 28
Change from Baseline in Red cell distribution width (RDW)
Timeframe: Baseline and up to Week 28
Change from Baseline in Blood Urea Nitrogen (BUN)
Timeframe: Baseline and up to Week 28
Change from Baseline in Aspartate amino-trasnferase (AST), Alanine amino-trasnferase (ALT), alkaline phosphatase, gamma- Glutamyl transferase (GGT) and creatine phosphokinase (CPK)
Timeframe: Baseline and up to Week 28
Change from Baseline in glucose, potassium, sodium and calcium, phosphorus, chloride and carbon dioxide (CO2)
Timeframe: Baseline and up to Week 28
Change from Baseline in creatinine, total and direct bilirubin
Timeframe: Baseline and up to Week 28
Change from Baseline in total protein and albumin
Timeframe: Baseline and up to Week 28
Change from Baseline in specific gravity of urine
Timeframe: Baseline and up to Week 28
Change from Baseline in potential of hydrogen (pH) of urine
Timeframe: Baseline and up to Week 28
Change from Baseline in glucose, protein, ketone, bilirubin, leukocyte, nitrite and urobilinogen levels in urine
Timeframe: Baseline and up to Week 28
Number of incidences and titers of anti- GSK3772847 antibodies
Timeframe: Up to Week 28
Serum concentration of GSK3772847
Timeframe: Week 0 post-dose, Week 1, Week 2, Week 4 and Week 8 pre dose, Week 12 pre and post dose, Week 16, Week 20, Week 24, Week 28
Free and total soluble Suppressor of tumorigenicity 2 (sST2) levels
Timeframe: Up to Week 28
Interventions:
Drug: GSK3772847
Drug: Placebo
Drug: Fluticasone propionate/salmeterol
Drug: Fluticasone propionate
Enrollment:
165
Observational study model:
Not applicable
Primary completion date:
2019-15-02
Time perspective:
Not applicable
Clinical publications:
Courtney Crim, Sally Stone, Valerie Millar, Sally Lettis, Elisabeth Bel, Andrew Menzies-Gow, Pascal Chanez, Sally Wenzel, Njira Lugogo, Eugene Bleecker. Interleukin-33 receptor inhibition in subjects with uncontrolled asthma: a randomized, placebo-controlled trial. J Allergy Clin Immunol Global. 2022;
DOI: https://doi.org/10.1016/j.jacig.2022.07.002
PMID: NULL
Medical condition
Asthma
Product
GSK3772847, fluticasone propionate, fluticasone propionate/salmeterol, salmeterol
Collaborators
Not applicable
Study date(s)
September 2017 to May 2019
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Age: At least 18 years of age at the time of signing the informed consent.
- Males and females: A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow highly effective contraceptive methods from 4 weeks prior to the first dose of study medication and until at least 16 weeks after the last dose of study medication and completion of the follow-up visit.
- Current smokers or former smokers with a smoking history more than or equal to 10 pack years.
- Presence of a known pre-existing, clinically important respiratory conditions (e.g. pneumonia, pneumothorax, atelectasis segmental or larger, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or other respiratory
Inclusion and exclusion criteria
Inclusion criteria:
- Age: At least 18 years of age at the time of signing the informed consent.
- Males and females: A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow highly effective contraceptive methods from 4 weeks prior to the first dose of study medication and until at least 16 weeks after the last dose of study medication and completion of the follow-up visit.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.
- A subject with a documented diagnosis of moderate severe asthma based on Global Initiative for Asthma (GINA) 2016 Guidelines, whose asthma has been managed with regular treatment of high dose ICS defined as FP 500 mcg twice daily (i.e. 1000 mcg total daily dose) or equivalent, and LABA for at least 4 months. Additional therapy with a leukotriene receptor antagonist (LTRA) is permissible.
- Airway reversibility of at least 12 percent and 200 milliliter (mL) in FEV1 at Screening (Visit 1), or documented reversibility prior to Screening (Visit 1), or documented history of bronchial hyper reactivity (e.g. fall in FEV1 from baseline of more than or equal to 20percent with standard doses of methacholine or histamine, or more than or equal to 15 percent with standardized hyperventilation, hypertonic saline or mannitol challenge) from a bronchoprovocation study [e.g. methacholine challenge prior to Screening (Visit 1)].
- ACQ-5 score more than or equal to 1.0 and less than 4.0 at Screening (Visit 1).
- Had at least one asthma exacerbation within 12 months prior to screening that required treatment with systemic corticosteroid and/or hospitalization.
- All subjects must be able to replace their current Short-Acting Beta2-Agonists (SABA) treatment with albuterol/salbutamol aerosol inhaler at Visit 1 for use as needed, per product label, for the duration of the study. Randomization inclusion criteria:
- ACQ-5 score more than or equal to 1.0 and less than 4.0 at Visit 2.
- Compliance with completion of the Daily eDiary reporting defined as completion of all questions/assessments on more than or equal to 4 of the last 7 days during the run-in period.
Exclusion criteria:
- Current smokers or former smokers with a smoking history more than or equal to 10 pack years.
- Presence of a known pre-existing, clinically important respiratory conditions (e.g. pneumonia, pneumothorax, atelectasis segmental or larger, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or other respiratory abnormalities) other than asthma.
- A pre-bronchodilator FEV1 less than 50 percent predicted of normal value at Screening (Visit 1).
- Subjects with a diagnosis of malignancy or in the process of investigation for a malignancy. Subjects with carcinoma that have not been in complete remission for at least 5 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the subject has been considered cured by treatment.
- Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at Screening (Visit 1) or within 3 months prior to first dose of study treatment.
- Site investigators will be provided with ECG over-read conducted by a centralized independent cardiologist, to assist in evaluation of subject eligibility.
- Weight: less than 50 kilograms (kg) and more than 150 kg.
- Regular use of systemic corticosteroids for conditions including asthma within 3 months prior to Screening (Visit 1).
- Subjects with high parasympathetic tone (e.g. trained athletes with baseline bradycardia) or chronic conditions associated with parasympathetic surges (e.g. migraines).
- Other conditions that could lead to elevated eosinophils such as hypereosinophilic syndromes. Subjects with a known, pre-existing parasitic infestation within 6 months prior to Screening (Visit 1).
- Clinically significant organic heart disease [e.g. Coronary artery disease (CAD), New York Heart Association (NYHA) Class III/IV heart failure].
- Ongoing infections (i.e. not resolved within 7 days prior to Screening [Visit 1]) or recurrent infections (i.e. requiring treatment for an identical diagnosis within 3 months) requiring systemic antibiotics Known, pre-existing parasitic infestations within 6 months prior to Screening.
- A subject must not have any clinically significant, uncontrolled condition, or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study.
- A known immunodeficiency such as human immunodeficiency virus infection.
- Subjects with allergy or intolerance to a monoclonal antibody or biologic or to any components of the formulation used in this study.
- Subjects with a history (or suspected history) of alcohol misuse or substance abuse within 2 years prior to Screening (Visit 1).
- Subjects who are unable to follow study instructions such as visit schedule, dosing directions, study eDiary completion, or use of a standard metered dose inhaler. Subjects who have known evidence of lack of adherence to controller medication and/or ability to follow physician’s recommendations. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
- Subjects who have previously participated in a study of GSK3772847.
- Use of the prohibited medications is not permitted within the defined time intervals prior to Screening (Visit 1) and throughout the study. Potential subjects should not be washed out of their medication solely for the purpose on enrolling in the trial.
- A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub investigator, study coordinator, or employee of the participating investigator.
- In the opinion of the investigator, any subject who is unable to read and/or would not be able to complete a diary card/questionnaire.
- Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study. Randomization exclusion criteria:
- Evidence of clinically significant abnormal laboratory tests during screening which are still abnormal upon repeat analysis and are not believed to be due to disease(s) present. Each Investigator will use his/her own discretion in determining the clinical significance of the abnormality.
- Evidence of clinically significant abnormal ECG findings at Visit 2.
- An abnormal and significant finding from 24-hour Holter monitoring at Screening (Visit 1). Investigators will be provided with Holter reviews conducted by an independent cardiologist to assist in evaluation of subject eligibility.
- Liver function at screening (Visit 1): ALT more than 2 x upper limit of normal (ULN) and bilirubin more than 1.5xULN (isolated bilirubin more than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35 percent); Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- Subjects with ongoing asthma exacerbation at the time of Visit 2.
- A pre-bronchodilator FEV1 less than 50 percent predicted of normal value at Visit 2.
- Positive pregnancy test at Visit 0, Screening (Visit 1) or Visit 2.
- Ongoing or recurrent infections requiring systemic antibiotics.
Trial location(s)
Location
GSK Investigational Site
Adairsville, Georgia, United States, 30103
Status
Study Complete
Location
GSK Investigational Site
Ann Arbor, Michigan, United States, 48109-5360
Status
Study Complete
Location
GSK Investigational Site
Bakersfield, California, United States, 93301
Status
Study Complete
Location
GSK Investigational Site
Baltimore, Maryland, United States, 21224
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35209
Status
Study Complete
Location
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599-7248
Status
Study Complete
Location
GSK Investigational Site
Charlotte, North Carolina, United States, 28277
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45231
Status
Study Complete
Location
GSK Investigational Site
Coral Gables, Florida, United States, 33134
Status
Study Complete
Location
GSK Investigational Site
Hialeah, Florida, United States, 33012
Status
Study Complete
Location
GSK Investigational Site
Long Beach, California, United States, 90806
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90017
Status
Study Complete
Location
GSK Investigational Site
Madison, Wisconsin, United States, 53792
Status
Study Complete
Location
GSK Investigational Site
Mooresville, North Carolina, United States, 28117
Status
Study Complete
Location
GSK Investigational Site
New Haven, Connecticut, United States, 06510
Status
Study Complete
Location
GSK Investigational Site
Newport Beach, California, United States, 92663
Status
Study Complete
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
Status
Study Complete
Location
GSK Investigational Site
Rochester, New York, United States, 14642
Status
Study Complete
Location
GSK Investigational Site
Scottsboro, Alabama, United States, 35768
Status
Study Complete
Location
GSK Investigational Site
Sherwood Park, Alberta, Canada, T8H 0N2
Status
Study Complete
Location
GSK Investigational Site
Saint Louis, Missouri, United States, 63108
Status
Study Complete
Location
GSK Investigational Site
Trois-Rivieres, Québec, Canada, G8T 7A1
Status
Study Complete
Location
GSK Investigational Site
Vancouver, British Columbia, Canada, V5Z 1M9
Status
Study Complete
Location
GSK Investigational Site
Vancouver, British Columbia, Canada, V6Z 1Y6
Status
Study Complete
Location
GSK Investigational Site
Williamsburg, Virginia, United States, 23188
Status
Study Complete
Location
GSK Investigational Site
Winter Park, Florida, United States, 32789
Status
Study Complete
Location
GSK Investigational Site
Woodville South, South Australia, Australia, 5011
Status
Study Complete
Study documents
Study report synopsis
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2019-15-02
Actual study completion date
2019-15-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website